Non-alcoholic fatty liver disease and metabolic syndrome after liver transplant

International Journal of Molecular Sciences

Volumn 17, Issue 4, 2016, Pages 1-11

  Gitto, Stefano ^a   Villa, Erica ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Liver transplant; Metabolic syndrome; Multifactorial disease; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ALPHA TOCOPHEROL; CORTICOSTEROID; CYCLOSPORIN; ELAFIBRANOR; LIRAGLUTIDE; OBETICHOLIC ACID; PIOGLITAZONE; RAPAMYCIN; TACROLIMUS; TELMISARTAN; TRANSCRIPTION FACTOR 7 LIKE 2; IMMUNOSUPPRESSIVE AGENT;

BARIATRIC SURGERY; BODY MASS; DIABETES MELLITUS; DIET THERAPY; ENERGY METABOLISM; EXERCISE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER FIBROSIS; LIVER GRAFT; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; REVIEW; TREATMENT OUTCOME; ADVERSE EFFECTS; ANIMAL; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; END STAGE LIVER DISEASE; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROCEDURES;

ANIMALS; CARCINOMA, HEPATOCELLULAR; END STAGE LIVER DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84962376823     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17040490     Document Type: Review

References (70)

1. Watt, K.D.; Pedersen, R.A.; Kremers, W.K.; Heimbach, J.K.; Charlton, M.R. Evolution of causes and risk factors for mortality post-liver transplant: Results of the NIDDK long-term follow-up study. Am. J. Transplant. 2010, 10, 1420-1427. [CrossRef] [PubMed]
2. Charco, R.; Cantarell, C.; Vargas, V.; Capdevila, L.; Lázaro, J.L.; Hidalgo, E.; Murio, E.; Margarit, C. Serum cholesterol changes in long-term survivors of liver transplantation: A comparison between cyclosporine and tacrolimus therapy. Liver Transpl. Surg. 1999, 5, 204-208. [CrossRef] [PubMed]
3. Bhagat, V.; Mindikoglu, A.L.; Nudo, C.G.; Schiff, E.R.; Tzakis, A.; Regev, A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transplant. 2009, 15, 1814-1820. [CrossRef] [PubMed]
4. Richards, J.; Gunson, B.; Johnson, J.; Neuberger, J. Weight gain and obesity after liver transplantation. Transpl. Int. 2005, 18, 461-466. [CrossRef] [PubMed]
5. Richardson, R.A.; Garden, O.J.; Davidson, H.I. Reduction in energy expenditure after liver transplantation. Nutrition 2001, 17, 585-589. [CrossRef]
6. Ferreira, L.G.; Santos, L.F.; Anastácio, L.R.; Lima, A.S.; Correia, M.I. Resting energy expenditure, body composition, and dietary intake: A longitudinal study before and after liver transplantation. Transplantation 2013, 96, 579-585. [CrossRef] [PubMed]
7. Anastácio, L.R.; Ferreira, L.G.; de Sena Ribeiro, H.; Lima, A.S.; Vilela, E.G.; Toulson Davisson Correia, M.I. Body composition and over-weight of liver transplant recipients. Transplantation 2011, 92, 947-951. [CrossRef] [PubMed]
8. Lane, J.T.; Dagogo-Jack, S. Approach to the patient with new-onset diabetes after transplant (NODAT). J. Clin. Endocrinol. Metab. 2011, 96, 3289-3297. [CrossRef] [PubMed]
9. Parekh, J.; Corley, D.A.; Feng, S. Diabetes, hypertension and hyperlipidemia: Prevalence over time and impact on long-term survival after liver transplantation. Am. J. Transplant. 2012, 12, 2181-2187. [CrossRef] [PubMed]
10. Li, D.W.; Lu, T.F.; Hua, X.W.; Dai, H.J.; Cui, X.L.; Zhang, J.J.; Xia, Q. Risk factors for new onset diabetes mellitus after liver transplantation: A meta-analysis. World J. Gastroenterol. 2015, 21, 6329-6340. [CrossRef] [PubMed]
11. Ling, Q.; Xie, H.; Lu, D.;Wei, X.; Gao, F.; Zhou, L.; Xu, X.; Zheng, S. Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population. J. Hepatol. 2013, 58, 271-277. [CrossRef] [PubMed]
12. Bianchi, G.; Marchesini, G.; Marzocchi, R.; Pinna, A.D.; Zoli, M. Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression. Liver Transplant. 2008, 14, 1648-1654. [CrossRef] [PubMed]
13. Singh, S.; Watt, K.D. Long-term medical management of the liver transplant recipient: What the primary care physician needs to know. Mayo Clin. Proc. 2012, 87, 779-790. [CrossRef] [PubMed]
14. Morrisett, J.D.; Abdel-Fattah, G.; Hoogeveen, R.; Mitchell, E.; Ballantyne, C.M.; Pownall, H.J.; Opekun, A.R.; Jaffe, J.S.; Oppermann, S.; Kahan, B.D. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J. Lipid Res. 2002, 43, 1170-1180. [PubMed]
15. Nikkilä, K.; Åberg, F.; Isoniemi, H. Transmission of LDLR mutation from donor through liver transplantation resulting in hypercholesterolemia in the recipient. Am. J. Transplant. 2014, 14, 2898-2902. [CrossRef] [PubMed]
16. Hryniewiecka, E.; Zegarska, J.; Paczek, L. Arterial hypertension in liver transplant recipients. Transplant. Proc. 2011, 43, 3029-3034. [CrossRef] [PubMed]
17. Zheng, J.; Wang, W.L. Risk factors of metabolic syndrome after liver transplantation. Hepatobiliary Pancreat. Dis. Int. 2015, 14, 582-587. [CrossRef]
18. Wilkinson, A.; Davidson, J.; Dotta, F.; Home, P.D.; Keown, P.; Kiberd, B.; Jardine, A.; Levitt, N.; Marchetti, P.; Markell, M.; et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin. Transplant. 2005, 19, 291-298. [CrossRef] [PubMed]
19. Ahn, H.Y.; Cho, Y.M.; Yi, N.J.; Suh, K.S.; Lee, K.U.; Park, K.S.; Kim, S.Y.; Lee, H.K. Predictive factors associated with the reversibility of post-transplantation diabetes mellitus following liver transplantation. J. Korean Med. Sci. 2009, 24, 567-570. [CrossRef] [PubMed]
20. Musavi, Z.; Azarpira, N.; Sangtarash, M.H.; Kordi, M.; Kazemi, K.; Geramizadeh, B.; Malek-Hosseini, S.A. Polymorphism of transcription factor-7-Like 2 (TCF7L2) gene and new-onset diabetes after liver transplantation. Int. J. Organ Transplant. Med. 2015, 6, 14-22. [PubMed]
21. Neal, D.A.; Brown, M.J.; Wilkinson, I.B.; Alexander, G.J. Mechanisms of hypertension after liver transplantation. Transplantation 2005, 79, 935-940. [CrossRef] [PubMed]
22. Giusto, M.; Lattanzi, B.; Di Gregorio, V.; Giannelli, V.; Lucidi, C.; Merli, M. Changes in nutritional status after liver transplantation. World J. Gastroenterol. 2014, 20, 10682-10690. [CrossRef] [PubMed]
23. Van den Ham, E.C.; Kooman, J.P.; Christiaans, M.H.; Leunissen, K.M.; van Hooff, J.P. Posttransplantation weight gain is predominantly due to an increase in body fat mass. Transplantation 2000, 70, 241-242. [PubMed]
24. Mercier, J.G.; Hokanson, J.F.; Brooks, G.A. Effects of cyclosporine A on skeletal muscle mitochondrial respiration and endurance time in rats. Am. J. Respir. Crit. Care Med. 1995, 151, 1532-1536. [CrossRef] [PubMed]
25. Rodríguez-Perálvarez, M.; Germani, G.; Darius, T.; Lerut, J.; Tsochatzis, E.; Burroughs, A.K. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: A systematic review and meta-analysis. Am. J. Transplant. 2012, 12, 2797-2814. [CrossRef] [PubMed]
26. Sakuma, K.; Yamaguchi, A. The functional role of calcineurin in hypertrophy, regeneration, and disorders of skeletal muscle. J. Biomed. Biotechnol. 2010, 2010. [CrossRef] [PubMed]
27. Rabkin, J.M.; Corless, C.L.; Rosen, H.R.; Olyaei, A.J. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am. J. Surg. 2002, 183, 595-599. [CrossRef]
28. Manzarbeitia, C.; Reich, D.J.; Rothstein, K.D.; Braitman, L.E.; Levin, S.; Munoz, S.J. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. Liver Transplant. 2001, 7, 93-99. [CrossRef] [PubMed]
29. Ojo, A.O.; Held, P.J.; Port, F.K.; Wolfe, R.A.; Leichtman, A.B.; Young, E.W.; Arndorfer, J.; Christensen, L.; Merion, R.M. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 2003, 349, 931-940. [CrossRef] [PubMed]
30. Rossetto, A.; Bitetto, D.; Bresadola, V.; Lorenzin, D.; Baccarani, U.; de Anna, D.; Bresadola, F.; Adani, G.L. Cardiovascular risk factors and immunosuppressive regimen after liver transplantation. Transplant. Proc. 2010, 42, 2576-2578. [CrossRef] [PubMed]
31. Neff, G.W.; Montalbano, M.; Tzakis, A.G. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant. Proc. 2003, 35, 209S-216S. [CrossRef]
32. Miyabara, E.H.; Conte, T.C.; Silva, M.T.; Baptista, I.L.; Bueno, C.; Fiamoncini, J.; Lambertucci, R.H.; Serra, C.S.; Brum, P.C.; Curi, T.; et al. Mammalian target of rapamycin complex 1 is involved in differentiation of regenerating myofibers in vivo. Muscle Nerve 2010, 42, 778-787. [CrossRef] [PubMed]
33. Zimmermann, A.; Zobeley, C.; Weber, M.M.; Lang, H.; Galle, P.R.; Zimmermann, T. Changes in lipid and carbohydrate metabolism under mTOR-and calcineurin-based immunosuppressive regimen in adult patients after liver transplantation. Eur. J. Intern. Med. 2016, 29, 104-109. [CrossRef] [PubMed]
34. Klintmalm, G.B.; Washburn, W.K.; Rudich, S.M.; Heffron, T.G.; Teperman, L.W.; Fasola, C.; Eckhoff, D.E.; Netto, G.J.; Katz, E. Corticosteroid-free immunosuppression with daclizumab in HCV+ liver transplant recipients: 1-Year interim results of the HCV-3 study. Liver Transplant. 2007, 13, 1521-1531. [CrossRef] [PubMed]
35. Contos, M.J.; Cales, W.; Sterling, R.K.; Luketic, V.A.; Shiffman, M.L.; Mills, A.S.; Fisher, R.A.; Ham, J.; Sanyal, A.J. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transplant. 2001, 7, 363-373. [CrossRef] [PubMed]
36. Iadevaia, M.; Giusto, M.; Giannelli, V.; Lai, Q.; Rossi, M.; Berloco, P.; Corradini, S.G.; Merli, M. Metabolic syndrome and cardiovascular risk after liver transplantation: A single-center experience. Transplant. Proc. 2012, 44, 2005-2006. [CrossRef] [PubMed]
37. Rodríguez-Perálvarez, M.; Germani, G.; Papastergiou, V.; Tsochatzis, E.; Thalassinos, E.; Luong, T.V.; Rolando, N.; Dhillon, A.P.; Patch, D.; O'Beirne, J.; et al. Early tacrolimus exposure after liver transplantation: Relationship with moderate/severe acute rejection and long-term outcome. J. Hepatol. 2013, 58, 262-270. [CrossRef] [PubMed]
38. Heisel, O.; Heisel, R.; Balshaw, R.; Keown, P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: A system-atic review and meta-analysis. Am. J. Transplant. 2004, 4, 583-595. [CrossRef] [PubMed]
39. Watt, K.D.; Charlton, M.R. Metabolic syndrome and liver transplantation: A review and guide to management. J. Hepatol. 2010, 53, 199-206. [CrossRef] [PubMed]
40. Ford, E.S.; Giles, W.H.; Dietz, W.H. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287, 356-359. [CrossRef] [PubMed]
41. Sprinzl, M.F.; Weinmann, A.; Lohse, N.; Tönissen, H.; Koch, S.; Schattenberg, J.; Hoppe-Lotichius, M.; Zimmermann, T.; Galle, P.R.; Hansen, T.; et al. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. Transpl. Int. 2013, 26, 67-74. [CrossRef] [PubMed]
42. Qin, N.; Yang, F.; Li, A.; Prifti, E.; Chen, Y.; Shao, L.; Guo, J.; Le Chatelier, E.; Yao, J.; Wu, L.; et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014, 513, 59-64. [CrossRef] [PubMed]
43. Fussner, L.A.; Heimbach, J.K.; Fan, C.; Dierkhising, R.; Coss, E.; Leise, M.D.; Watt, K.D. Cardiovascular disease after liver transplantation: When, what, and who is at risk. Liver Transplant. 2015, 21, 889-896. [CrossRef] [PubMed]
44. Pagadala, M.; Dasarathy, S.; Eghtesad, B.; McCullough, A.J. Posttransplant metabolic syndrome: An epidemic waiting to happen. Liver Transplant. 2009, 15, 1662-1670. [CrossRef] [PubMed]
45. Burra, P.; Germani, G. Orthotopic liver transplantation in non-alcoholic fatty liver disease patients. Rev. Recent Clin. Trials 2014, 9, 210-216. [CrossRef] [PubMed]
46. Dureja, P.; Mellinger, J.; Agni, R.; Chang, F.; Avey, G.; Lucey, M.; Said, A. NAFLD recurrence in liver transplant recipients. Transplantation 2011, 91, 684-689. [CrossRef] [PubMed]
47. Malik, S.M.; de Vera, M.E.; Fontes, P.; Shaikh, O.; Sasatomi, E.; Ahmad, J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transplant. 2009, 15, 1843-1851. [CrossRef] [PubMed]
48. Finkenstedt, A.; Auer, C.; Glodny, B.; Posch, U.; Steitzer, H.; Lanzer, G.; Pratschke, J.; Biebl, M.; Steurer, M.; Graziadei, I.; et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin. Gastroenterol. Hepatol. 2013, 11, 1667-1672. [CrossRef] [PubMed]
49. Watt, K.D.; Dierkhising, R.; Fan, C.; Heimbach, J.K.; Tillman, H.; Goldstein, D.; Thompson, A.; Krishnan, A.; Charlton, M.R. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: Insight into mechanisms of disease. Am. J. Transplant. 2013, 13, 2450-2457. [CrossRef] [PubMed]
50. Dumortier, J.; Giostra, E.; Belbouab, S.; Morard, I.; Guillaud, O.; Spahr, L.; Boillot, O.; Rubbia-Brandt, L.; Scoazec, J.Y.; Hadengue, A. Non-alcoholic fatty liver disease in liver transplant recipients: Another story of "seed and soil". Am. J. Gastroenterol. 2010, 105, 613-620. [CrossRef] [PubMed]
51. Mikolasevic, I.; Orlic, L.; Hrstic, I.; Milic, S. Metabolic syndrome and non-alcoholic fatty liver disease after liver or kidney transplantation. Hepatol. Res. 2015. [CrossRef] [PubMed]
52. Gitto, S.; Vitale, G.; Villa, E.; Andreone, P. Treatment of nonalcoholic steatohepatitis in adults: Present and future. Gastroenterol. Res. Pract. 2015, 2015. [CrossRef] [PubMed]
53. Kim, F.; Pham, M.; Maloney, E.; Rizzo, N.O.; Morton, G.J.; Wisse, B.E.; Kirk, E.A.; Chait, A.; Schwartz, M.W. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1982-1988. [CrossRef] [PubMed]
54. Tilg, H.; Moschen, A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010, 52, 1836-1846. [CrossRef] [PubMed]
55. Kouz, J.; Vincent, C.; Leong, A.; Dorais, M.; Räkel, A. Weight gain after orthotopic liver transplantation: Is nonalcoholic fatty liver disease cirrhosis a risk factor for greater weight gain? Liver Transplant. 2014, 20, 1266-1274. [CrossRef] [PubMed]
56. Merli, M.; Giusto, M.; Riggio, O.; Gentili, F.; Molinaro, A.; Attili, A.F.; Ginanni Corradini, S.; Rossi, M. Improvement of nutritional status in malnourished cirrhotic patients one year after liver transplantation. e-SPEN 2011, 6, e142-e147. [CrossRef]
57. Charlton, M. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr. Opin. Organ Transplant. 2013, 18, 251-258. [CrossRef] [PubMed]
58. Krasnoff, J.B.; Vintro, A.Q.; Ascher, N.L.; Bass, N.M.; Paul, S.M.; Dodd, M.J.; Painter, P.L. A randomized trial of exercise and dietary counseling after liver transplantation. Am. J. Transplant. 2006, 6, 1896-1905. [CrossRef] [PubMed]
59. Loria, P.; Adinolfi, L.E.; Bellentani, S.; Bugianesi, E.; Grieco, A.; Fargion, S.; Gasbarrini, A.; Loguercio, C.; Lonardo, A.; Marchesini, G.; et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease: A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig. Liver Dis. 2010, 42, 272-282. [CrossRef] [PubMed]
60. Ratziu, V.; Bellentani, S.; Cortez-Pinto, H.; Day, C.; Marchesini, G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 2010, 53, 372-384. [CrossRef] [PubMed]
61. Farrell, G.C.; Chitturi, S.; Lau, G.K.; Sollano, J.D.; Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: Executive summary. J. Gastroenterol. Hepatol. 2007, 22, 775-777. [CrossRef] [PubMed]
62. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J.; American Gastroenterological Association; American Association for the Study of Liver Diseases; et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142, 1592-1609. [PubMed]
63. Promrat, K.; Kleiner, D.E.; Niemeier, H.M.; Jackvony, E.; Kearns, M.; Wands, J.R.; Fava, J.L.; Wing, R.R. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51, 121-129. [CrossRef] [PubMed]
64. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): Description of lifestyle intervention. Diabetes Care 2002, 25, 2165-2171.
65. George, A.; Bauman, A.; Johnston, A.; Farrell, G.; Chey, T.; George, J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009, 50, 68-76. [CrossRef] [PubMed]
66. Hallsworth, K.; Fattakhova, G.; Hollingsworth, K.G.; Thoma, C.; Moore, S.; Taylor, R.; Day, C.P.; Trenell, M.I. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011, 60, 1278-1283. [CrossRef] [PubMed]
67. Kantartzis, K.; Thamer, C.; Peter, A.; Machann, J.; Schick, F.; Schraml, C.; Königsrainer, A.; Königsrainer, I.; Kröber, S.; Niess, A.; et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009, 58, 1281-1288. [CrossRef] [PubMed]
68. Targher, G.; Marra, F.; Marchesini, G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: Causal effect or epiphenomenon? Diabetologia 2008, 51, 1947-1953. [CrossRef] [PubMed]
69. Lassailly, G.; Caiazzo, R.; Pattou, F.; Mathurin, P. Perspectives on treatment for nonalcoholic steatohepatitis. Gastroenterology 2016. [CrossRef] [PubMed]
70. Karlas, T.; Kollmeier, J.; Böhm, S.; Müller, J.; Kovacs, P.; Tröltzsch, M.; Weimann, A.; Bartels, M.; Rosendahl, J.; Mössner, J.; et al. Noninvasive characterization of graft steatosis after liver transplantation. Scand. J. Gastroenterol. 2015, 50, 224-232. [CrossRef] [PubMed]